Considering dose in pharmacological therapies for heart failure.

Lancet

Department of Integrated Medical Sciences, Florida Atlantic University, Boca Raton, FL 33431, USA. Electronic address:

Published: January 2021

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(21)00089-1DOI Listing

Publication Analysis

Top Keywords

considering dose
4
dose pharmacological
4
pharmacological therapies
4
therapies heart
4
heart failure
4
considering
1
pharmacological
1
therapies
1
heart
1
failure
1

Similar Publications

Variable stressor exposure shapes fitness within and across generations.

Sci Rep

January 2025

Aquatic Ecology, Department of Biology, Lund University, Lund, Sweden.

Environmental variation has long been considered a key driver of evolutionary change, predicted to shape different strategies, such as genetic specialization, plasticity, or bet-hedging to maintain fitness. However, little evidence is available with regards to how the periodicity of stressors may impact fitness across generations. To address this gap, I conducted a reciprocal split-brood experiment using the freshwater crustacean, Daphnia magna, and an ecologically relevant environmental stressor, ultraviolet radiation (UVR).

View Article and Find Full Text PDF

Vasoplegia in Heart, Lung, or Liver Transplantation: A Narrative Review.

J Cardiothorac Vasc Anesth

January 2025

Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA.

Vasoplegia is a pathophysiologic state of hypotension in the setting of normal or high cardiac output and low systemic vascular resistance despite euvolemia and high-dose vasoconstrictors. Vasoplegia in heart, lung, or liver transplantation is of particular interest because it is common (approximately 29%, 28%, and 11%, respectively), is associated with adverse outcomes, and because the agents used to treat vasoplegia can affect immunosuppressive and other drug metabolism. This narrative review discusses the pathophysiology, risk factors, and treatment of vasoplegia in patients undergoing heart, lung, and liver transplantation.

View Article and Find Full Text PDF

Ex vivo electrophysiological evaluation of peripheral nerve functioning following exposition of adult mice to the organophosphorus pesticide chlormephos.

Environ Toxicol Pharmacol

January 2025

Université Paris-Saclay, CEA, Institut des sciences du vivant Frédéric Joliot, Département Médicaments et Technologies pour la Santé (DMTS), Service d'Ingénierie Moléculaire pour la Santé (SIMoS), EMR CNRS/CEA 9004, 91191 Gif-sur-Yvette, France. Electronic address:

The organophosphorus pesticide chlormephos was tested for its potential peripheral neurotoxicity by analyzing the diphasic compound action potential (CAP) of sciatic nerves isolated from adult mice chronically exposed to a sub-lethal dose of this pesticide, compared with control age-matched animals being only exposed to the vehicle. No significant modification was detected between chlormephos-exposed and control groups in their nerve responsiveness to stimulus. Furthermore, similar values of CAP kinetic variables were obtained from the two mouse groups.

View Article and Find Full Text PDF

Adherence to community-based lung cancer screening in the Yorkshire Lung Screening Trial.

Lung Cancer

January 2025

Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. Electronic address:

Introduction: Lung cancer screening saves lives by detecting cancers early, but continued adherence to screening rounds is required for participants to experience the maximum clinical benefit. Here we describe factors associated with screening adherence in the Yorkshire Lung Screening Trial.

Methods: All eligible individuals following baseline (prevalent) screening were invited for a biennial incident screen in a community setting.

View Article and Find Full Text PDF

Recent advances in oncology research have highlighted the promising synergy between low-dose radiation therapy (LDRT) and immunotherapies, with growing evidence highlighting the unique benefits of the combination. LDRT has emerged as a potent tool for stimulating the immune system, triggering systemic antitumor effects by remodeling the tumor microenvironment. Notably, LDRT demonstrates remarkable efficacy even in challenging metastatic sites such as the liver (uveal) and brain (cutaneous), particularly in advanced melanoma stages.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!